Exclusion Initial therapy First line or initial treatment for ANCA Wording revised (A) Criteria Indication for Control of vasculitic activity in rare trial of ANCA positive systemic necrotising vasculitis Two indications have been used. systemic necrotising vasculitis failing to All qualifying patients will only receive 6 months use failing to respond to corticosteroids and respond to corticosteroids and cytotoxic cytotoxic immunosuppression treatment. immunosuppression. A second indication supports the further Relapse in ANCA positive systemic necrotising treatment of responders who relapse following vasculitis resistant following response to Ig cessation of Ig therapy. Different qualifying and therapy review criteria will apply. (A)
Exclusion Criteria Initial therapy First line or initial treatment for ANCA Wording revised (A) Indication for use Control of vasculitic activity in rare of systemic necrotising vasculitis failing to respond to corticosteroids and cytotoxic immunosuppression. ANCA positive systemic necrotising vasculitis failing to respond to corticosteroids and cytotoxic immunosuppression Relapse in ANCA positive systemic necrotising vasculitis resistant following response to Ig therapy Two indications have been used. All qualifying patients will only receive 6 months treatment. A second indication supports the further treatment of responders who relapse following cessation of Ig therapy. Different qualifying and review criteria will apply. (A) trial
anti-neutrophil-cytoplasmic-antibody-anca-proteinase-3-pr3-or-myeloperoxidase-mpo-positive-systemic-necrotising-vasculitis.DOCX